Cite
A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.
MLA
de Bruin, Renée C. G., et al. “A Bispecific Nanobody Approach to Leverage the Potent and Widely Applicable Tumor Cytolytic Capacity of Vγ9Vδ2-T Cells.” OncoImmunology, vol. 7, no. 1, Jan. 2018, p. N.PAG. EBSCOhost, https://doi.org/10.1080/2162402X.2017.1375641.
APA
de Bruin, R. C. G., Veluchamy, J. P., Lougheed, S. M., Schneiders, F. L., Lopez-Lastra, S., Lameris, R., Stam, A. G., Sebestyen, Z., Kuball, J., Molthoff, C. F. M., Hooijberg, E., Roovers, R. C., Santo, J. P. D., van Bergen en Henegouwen, P. M. P., Verheul, H. M. W., de Gruijl, T. D., & van der Vliet, H. J. (2018). A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. OncoImmunology, 7(1), N.PAG. https://doi.org/10.1080/2162402X.2017.1375641
Chicago
de Bruin, Renée C. G., John P. Veluchamy, Sinéad M. Lougheed, Famke L. Schneiders, Silvia Lopez-Lastra, Roeland Lameris, Anita G. Stam, et al. 2018. “A Bispecific Nanobody Approach to Leverage the Potent and Widely Applicable Tumor Cytolytic Capacity of Vγ9Vδ2-T Cells.” OncoImmunology 7 (1): N.PAG. doi:10.1080/2162402X.2017.1375641.